We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





New COVID-19 Vaccine Candidate Uses Existing Deactivated Rabies Vaccine as Vehicle for Coronavirus Proteins

By HospiMedica International staff writers
Posted on 21 May 2020
Print article
Image: New COVID-19 Vaccine Candidate Uses Existing Deactivated Rabies Vaccine as Vehicle for Coronavirus Proteins (Photo courtesy of Thomas Jefferson University)
Image: New COVID-19 Vaccine Candidate Uses Existing Deactivated Rabies Vaccine as Vehicle for Coronavirus Proteins (Photo courtesy of Thomas Jefferson University)
Thomas Jefferson University (Philadelphia, PA, USA) has signed an exclusive deal with vaccine innovator Bharat Biotech International (Hyderabad, India) to develop a new vaccine candidate for COVID-19 invented at Jefferson.

Under the license agreement, Bharat Biotech gains exclusive rights to develop, market and deliver Jefferson’s vaccine across the world excluding countries such as US, Europe, Japan etc., where Jefferson continues to seek partners. With support from the Department of Biotechnology, Govt. of India, Bharat Biotech aims to get into human trials as soon as December 2020.

Of the 90 or so coronavirus vaccines in development, about 25% use an established vaccine to act as a “carrier” or vector for the target virus, in this case, the coronavirus SARS-COV-2 spike protein. Not every vaccine produces the same level of the immune response. The vector used in this new vaccine is a deactivated rabies vaccine that is known to generate a rigorous but safe immune reaction that confers life-long protection, and has been proven safe for all populations, including children and pregnant women. The vaccine developed in January this year recently completed preliminary tests in animal models and showed a strong antibody response in mice receiving the vaccine. The researchers are currently testing whether vaccinated animals are protected from SARS-CoV-2 infection with results expected in June.

“We are leveraging the properties of a very effective vaccine – one that provides life-long immunity against one of the biggest global threats of our time,” said Dr. Mark Tykocinski MD, Provost and Executive Vice President for Academic Affairs of Thomas Jefferson University, and Dean of its Sidney Kimmel Medical College. “Rather than go with an untested approach, we have a leg-up by using a vaccine that is safe, effective, and exceptionally good at creating a strong immune response – which is something not every vaccine can do.”

“Our partnership with Bharat Biotech will accelerate our vaccine candidate through the next phases of development,” said Infectious Diseases expert Professor Matthias Schnell who directs The Jefferson Vaccine Institute and chairs Jefferson’s Department of Microbiology and Immunology. “We will be able to complete animal testing and move to phase 1 clinical trial rapidly.”

“In view of the imminent demand for an effective vaccine, Bharat Biotech is pleased to collaborate with Thomas Jefferson, USA towards developing a new vaccine for COVID-19 using an inactivated rabies vector platform,” said Dr. Krishna Mohan, Chief Executive Officer of Bharat Biotech. “We are particularly excited about this technology since the basic proof of concept has been established while using it for other pandemic infectious diseases. Bharat Biotech is committed to global public health and will be involved in an end to end development of the vaccine including comprehensive clinical trials to achieve commercial licensure.”

Related Links:
Thomas Jefferson University
Bharat Biotech International


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
EEG System
BRAIN QUICK

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.